ACM
FLXN

AlphaCrest Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

AlphaCrest Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,400
Closed -$129K – 1322
2020
Q3 		$129K Buy
+12,400
New +$152K 0.01% 1066
2019
Q3 		– Sell
-16,800
Closed -$207K – 1378
2019
Q2 		$207K Sell
16,800
-500
-3% -$5.77K 0.02% 964
2019
Q1 		$216K Buy
+17,300
New +$231K 0.03% 762

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

AlphaCrest Capital Management's FLXN Position: Q4 2020 in Review

AlphaCrest Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2020, closing a stake of 12,400 shares — an estimated $129K sold.

AlphaCrest Capital Management first reported a position in FLXN in Q1 2019 and held it in 3 quarters. The position peaked at $216K in Q1 2019. 141 funds tracked by Wall St. Rank hold FLXN as of Q4 2020.

  • AlphaCrest Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • AlphaCrest Capital Management sold 12,400 Flexion Therapeutics, Inc. shares in Q4 2020, an estimated $129K.
  • AlphaCrest Capital Management first reported a position in Flexion Therapeutics, Inc. in Q1 2019 and held it in 3 quarters.
  • AlphaCrest Capital Management's Flexion Therapeutics, Inc. position peaked at $216K in Q1 2019.
  • 141 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2020.

Based on AlphaCrest Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.